The Australian Government and Mission Funding Partners have awarded a total of $50.16 million to Medical Research Future Fund (MRFF) initiatives under the Mission:
|
Initiative |
Institution |
Commitment (million) |
|
Zero Childhood Cancer Initiative |
University of New South Wales |
$5.00 |
|
Australian and New Zealand Children’s Haematology/Oncology Group (ANZCHOG) |
Monash University |
$2.50 |
|
Australian and New Zealand Children’s Haematology/Oncology Group (ANZCHOG) |
Monash University (co-funded with Financial Markets Foundation for Children, the Robert Connor Dawes Foundation and Carrie’s Beanies 4 Brain Cancer) |
$7.16 |
|
Cooperative Trials Group for Neuro-Oncology (COGNO) |
University of Sydney |
$2.50 |
|
COZMOS: Phase I/Ib trial of COmbined 5'-aZacitidine and carboplatin for recurrent/refractory paediatric brain and solid tuMOurs |
Monash University (co-funded with Carrie’s Beanies 4 Brain Cancer) |
$0.25 |
|
SJ-ELiOT: St Jude - Phase 1 Evaluation of LY2606368, molecularly-targeted CHK1/2i Therapy, in combination with cyclophosphamide or gemcitabine for children and adolescents with refractory or recurrent medulloblastoma brain tumours |
Monash University (co-funded with Carrie’s Beanies 4 Brain Cancer) |
$0.45 |
|
MAGMA: Multi-Arm GlioblastoMa Australasia Trial |
University of Sydney (co-funded with Carrie’s Beanies 4 Brain Cancer and the Mark Hughes Foundation) |
$2.42 |
|
PICCOG: PARP and Immune Checkpoint inhibitor COmbination for relapsed IDH-mutant high-grade Glioma |
University of Sydney |
$1.39 |
|
FET-PET in Glioma (FIG Study) |
La Trobe University |
$1.25 |
|
LUMOS: Low & intermediate grade glioma umbrella study of molecular guided therapies |
University of Sydney |
$0.50 |
|
Role of the NKp44-PDGF-DD axis in glioblastoma |
University of Melbourne |
$0.57 |
|
PARC: A Phase I/II study evaluating the safety and activity of pegylated recombinant human arginase (BCT-100) relapsed/refractory cancers of children and young adults |
Monash University |
$0.48 |
|
Targeted invadapodia to treat glioblastomas |
University of Melbourne |
$0.38 |
|
BRAIN: Brain cancer Rehabilitation, Assessment, Intervention of survivor Needs |
University of Sydney |
$4.97 |
|
A new nurse-led intervention to re-engage childhood brain cancer survivors |
University of New South Wales |
$1.94 |
|
Responding to need: technology-enhanced brain cancer survivorship |
University of Melbourne |
$2.62 |
|
MET-MED Trial: A phase III randomised double-blind placebo-controlled trial of metformin for cognitive recovery and white matter growth in paediatric medulloblastoma patients |
Monash University |
$0.88 |
|
CONNECT 1903: A pilot and surgical study of larotrectinib for disease control in children with newly-diagnosed high-grade glioma with NTRK fusion |
Monash University |
$0.32 |
|
LOGGIC: A phase III, randomised international multi-centre trial for LOw Grade Glioma In Children and adolescents |
University of New South Wales |
$1.13 |
|
LUMOS: Low and Anaplastic Grade Glioma Umbrella Study of Molecular Guided TherapieS |
University of Sydney |
$1.98 |
|
GLIMMER: Glioma Liquid biopsy and Multiomic-Monitoring Enabled Research platform |
The Walter and Eliza Hall Institute of Medical Research |
$4.55 |
|
A new targeted combination therapy with matched biomarker to treat intractable glioblastoma |
University of New South Wales |
$0.58 |
|
“Off-the-shelf” CAR-T cell immunotherapy for brain cancer |
The Council of the Queensland Institute of Medical Research |
$0.33 |
|
Supporting Australian Brain Cancer Research with an integrated network of platforms |
University of Sydney |
$5.99 |
In addition to co-funding MRFF opportunities, Mission Funding Partners have committed $59.54 million in initiatives under the Mission that are funded and managed independently.
Page last updated on 16 May 2023